{"url":"https://lda.senate.gov/api/v1/filings/1e21beed-4128-4fb9-bddf-e9d93cd676fb/","filing_uuid":"1e21beed-4128-4fb9-bddf-e9d93cd676fb","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/1e21beed-4128-4fb9-bddf-e9d93cd676fb/print/","filing_document_content_type":"text/html","income":null,"expenses":"810000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Steve Giuli, Vice President of Government Affairs & Trade Relations","dt_posted":"2025-04-21T16:27:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2400 N. COMMERCE PARKWAY","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WESTON","registrant_state":"FL","registrant_zip":"33326","registrant":{"id":310973,"url":"https://lda.senate.gov/api/v1/registrants/310973/","house_registrant_id":38623,"name":"APOTEX CORP.","description":"Generic pharmaceutical manufacturer","address_1":"2400 N. COMMERCE PARKWAY","address_2":null,"address_3":null,"address_4":null,"city":"WESTON","state":"FL","state_display":"Florida","zip":"33326","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE GIULI","contact_telephone":"+1 954-384-8007","dt_updated":"2026-01-30T15:29:14.471073-05:00"},"client":{"id":183737,"url":"https://lda.senate.gov/api/v1/clients/183737/","client_id":12,"name":"APOTEX CORP.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"FL","state_display":"Florida","country":"US","country_display":"United States of America","ppb_state":"FL","ppb_state_display":"Florida","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2006-07-20"},"lobbying_activities":[{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Federal policy relating to requiring the Department of Defense to purchase domestically manufactured generic drugs and use active pharmaceutical ingredients and key starting materials sourced domestically or from eligible countries; and Federal policy relating to providing incentives to spur domestic manufacturing of generic drugs.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to the implementation of a pharmaceutical manufacturer reliability rating system and incentives in the Medicare program for providers to purchase generic drugs from manufacturers with higher reliability ratings; and Federal policy relating to the structure of the Department of Health and Human Services.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"America First Trade Policy Presidential Memorandum, provisions relating to a review of United States trade policies and agreements and the exemption of pharmaceuticals from tariffs; Executive Orders 14193, 14197, 14231, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals from such tariffs; Reciprocal Trade and Tariffs Presidential Memorandum, provisions relating to implementing reciprocal tariffs on countries that impose import duties on products from the United States and the exemption of pharmaceuticals from tariffs; and S.J.Res.37, provisions relating to terminating the national emergency declared on February 1, 2025, by the President in Executive Order 14193.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"APOTEX INC.","contribution":"0.00","ownership_percentage":"0.00","address":"150 Signet Drive","city":"Toronto","state":"ON","state_display":"Ontario","country":"CA","country_display":"Canada","ppb_city":"Toronto","ppb_state":"ON","ppb_state_display":"Ontario","ppb_country":"CA","ppb_country_display":"Canada"}],"affiliated_organizations":[]}